作者
Wouter Korver, Mary Carsillo, Josh Yuan, Neeraja Idamakanti, Matthew Wagoner, Pu Shi, Cindy Q Xia, Glennda Smithson, Lachy McLean, Jonathan Zalevsky, Eric R Fedyk
发表日期
2019/8/1
期刊
Journal of Pharmacology and Experimental Therapeutics
卷号
370
期号
2
页码范围
182-196
出版商
American Society for Pharmacology and Experimental Therapeutics
简介
Ectoenzyme CD38 is increased on lymphocytes in response to an antigenic challenge and it is hypothesized that targeting these activated lymphocytes could ameliorate pathologic activities in autoimmune diseases. The cynomolgus monkey is an appropriate model for assessing potential effects of targeting CD38 in humans because these species exhibit similar expression profiles. TAK-079 is a human monoclonal antibody (IgG1λ) that binds to CD38 and lyses bound cells by complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity. TAK-079 binds to monkey CD38 with an affinity at EC50 4.5 nM, and the potential activity of TAK-079 was investigated in a monkey collagen-induced arthritis model of autoimmune disease. Prophylactic administration of TAK-079 (3 mg/kg i.v. weekly) was well tolerated and prevented arthritis development compared with vehicle-treated control animals …
引用总数
2020202120222023202473664